Cargando…
Topical bevacizumab for the treatment of corneal vascularization in dogs: A case series
OBJECTIVE: To evaluate the effect and safety of topical anti‐human vascular endothelial growth factor bevacizumab in dogs with persistent corneal vascularization. ANIMALS STUDIED: Prospective case series of 15 adult dogs (20 eyes). PROCEDURES: Dogs received 0.25% bevacizumab eye drops BID for 28 day...
Autores principales: | Muellerleile, Lisa‐Marie, Bernkopf, Michael, Wambacher, Michael, Nell, Barbara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292418/ https://www.ncbi.nlm.nih.gov/pubmed/34487608 http://dx.doi.org/10.1111/vop.12931 |
Ejemplares similares
-
Serum vascular endothelial growth factor changes and safety after topical anti‐human VEGF antibody bevacizumab in healthy dogs
por: Muellerleile, Lisa‐Marie, et al.
Publicado: (2019) -
Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization
por: Al-Debasi, Tariq, et al.
Publicado: (2017) -
Efficacy of Topical Bevacizumab in High-Risk Corneal Transplant Survival
por: Bhatti, Nasir, et al.
Publicado: (2013) -
Case Reports for Topical Treatment of Corneal Ulcers with a New Matrix Therapy Agent or RGTA(®) in Dogs
por: Martinez, Jessica A., et al.
Publicado: (2019) -
Ranibizumab Injection for Corneal Neovascularization Refractory to Bevacizumab Treatment
por: Ahn, Ye Jin, et al.
Publicado: (2014)